These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 6178461)

  • 21. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels.
    DiMaio MS; Baumgarten A; Greenstein RM; Saal HM; Mahoney MJ
    N Engl J Med; 1987 Aug; 317(6):342-6. PubMed ID: 2439909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of a collaborative university-commercial maternal serum alpha-fetoprotein screening program: a model for tertiary center outreach.
    Evans MI; Belsky RL; Clementino NA; Shlagor P; Brieger G; Koppitch FC; Syner FN; Rodriguez SE; Sokol RJ
    Am J Obstet Gynecol; 1987 Jun; 156(6):1441-9. PubMed ID: 2438935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is maternal alpha-fetoprotein screening still of value in a low-risk area for neural tube defects?
    Hooker JG; Lucas M; Richards BA; Shirley IM; Thompson BD; Ward RH
    Prenat Diagn; 1984; 4(1):29-33. PubMed ID: 6203108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects.
    Wald NJ; Cuckle H; Brock JH; Peto R; Polani PE; Woodford FP
    Lancet; 1977 Jun; 1(8026):1323-32. PubMed ID: 69055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maternal serum alpha-fetoprotein screening: low and high values for detection of genetic abnormalities.
    Simpson JL; Baum LD; Marder R; Elias S; Ober C; Martin AO
    Am J Obstet Gynecol; 1986 Sep; 155(3):593-7. PubMed ID: 2428249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
    Crossley JA; Aitken DA; Berry E; Connor JM
    J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of normal MSAFP screening on maternal age for genetic amniocentesis.
    Ganiats TG; Berry CC; Fullerton JT
    J Clin Epidemiol; 1990; 43(11):1143-8. PubMed ID: 1700812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.
    Wald NJ; Kennard A; Densem JW; Cuckle HS; Chard T; Butler L
    BMJ; 1992 Aug; 305(6850):391-4. PubMed ID: 1382768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for fetal malformations using ultrasound and measurements of alpha-fetoprotein in maternal serum.
    Persson PH; Kullander S; Gennser G; Grennert L; Laurell CB
    Br Med J (Clin Res Ed); 1983 Mar; 286(6367):747-9. PubMed ID: 6186332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maternal serum alpha-fetoprotein monitoring. Council on Scientific affairs.
    JAMA; 1982 Mar; 247(10):1478-81. PubMed ID: 6173496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for Down's syndrome and neural tube defect in Croatia. A regional prospective study.
    Brajenović-Milić B; Tislarić D; Bacić J; Paravić J; Slivar AE; Kapovic M; Kosec V; Ristic S; Rajhvajn B
    Fetal Diagn Ther; 1998; 13(6):367-71. PubMed ID: 9933821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical interpretation of maternal serum alpha-fetoprotein concentrations.
    Adams MJ; Windham GC; James LM; Greenberg F; Clayton-Hopkins JA; Reimer CB; Oakley GP
    Am J Obstet Gynecol; 1984 Feb; 148(3):241-54. PubMed ID: 6198913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of the value of measuring maternal serum alpha-fetoprotein for the antenatal diagnosis of neural tube defects.
    Tidy J
    Arch Gynecol Obstet; 1989; 244(3):133-6. PubMed ID: 2472120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-fetoprotein.
    Drugan A; Dvorin E; Obrien JE; Johnson MP; Evans MI
    Curr Opin Obstet Gynecol; 1991 Apr; 3(2):230-4. PubMed ID: 1717020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neural tube defects: epidemiology, detection, and prevention.
    Cohen FL
    J Obstet Gynecol Neonatal Nurs; 1987; 16(2):105-15. PubMed ID: 2437270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
    Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
    Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avoidance of anencephalic and spina bifida births by maternal serum-alphafetoprotein screening.
    Ferguson-Smith MA; Rawlinson HA; May HM; Tait HA; Vince JD; Gibson AA; Robinson HP; Ratcliffe JG
    Lancet; 1978 Jun; 1(8078):1330-3. PubMed ID: 78097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated maternal serum alpha-fetoprotein with normal ultrasound: is amniocentesis always appropriate? A review of 26,069 screened patients.
    Richards DS; Seeds JW; Katz VL; Lingley LH; Albright SG; Cefalo RC
    Obstet Gynecol; 1988 Feb; 71(2):203-7. PubMed ID: 2447540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.